Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

LRMR holding history

Larimar Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

LRMR overviewAll 13F holders of LRMRFull Q2 2026 holdings

Shares (Q2 2026)
144,326
Value
$440.2K
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of LRMR by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026144,326$440.2K<0.1%+114,627+386.0%AddedHolders
Q1 202629,699$133.6K<0.1%−84,881−74.1%ReducedHolders
Q4 2025114,580$436.5K<0.1%−143,419−55.6%ReducedHolders
Q3 2025257,999$833.3K<0.1%+149,662+138.1%AddedHolders
Q2 2025108,337$313.1K<0.1%+63,427+141.2%AddedHolders
Q1 202544,910$96.6K<0.1%−8,221−15.5%ReducedHolders
Q4 202453,131$205.6K<0.1%+33,257+167.3%AddedHolders
Q3 202419,874$130.2K<0.1%+2,202+12.5%AddedHolders
Q2 202417,672$128.1K<0.1%−8,926−33.6%ReducedHolders
Q1 202426,598$201.9K<0.1%−1,441−5.1%ReducedHolders
Q4 202328,039$127.6K<0.1%+13,986+99.5%AddedHolders
Q3 202314,053$55.5K<0.1%−14,632−51.0%ReducedHolders
Q2 202328,685$89.8K<0.1%+22,743+382.7%AddedHolders
Q1 20235,942$26.9K<0.1%+5,870+8,152.8%AddedHolders
Q4 202272$297<0.1%−3,273−97.8%ReducedHolders
Q3 20223,345$11.0K<0.1%+2,744+456.6%AddedHolders
Q2 2022601$1.00K<0.1%−1,132−65.3%ReducedHolders
Q1 20221,733$7.00K<0.1%+612+54.6%AddedHolders
Q4 20211,121$12.0K<0.1%+1,113+13,912.5%AddedHolders
Q3 20218$00.0%00.0%UnchangedHolders
Q2 20218$00.0%00.0%UnchangedHolders
Q1 20218$00.0%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.